+关注
admaris
暂无个人介绍
IP属地:未知
3
关注
4
粉丝
0
主题
0
勋章
主贴
热门
admaris
2021-11-29
nice
Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant<blockquote>辉瑞计划提高新冠药物产量以对抗奥密克戎病毒变种,股价上涨</blockquote>
admaris
2021-11-16
nice
Rivian rose nearly 10% in morning trade and hit an all-time high at 164.19 dollars<blockquote>Rivian早盘上涨近10%,创下164.19美元的历史新高</blockquote>
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4098950502646600","uuid":"4098950502646600","gmtCreate":1635847908614,"gmtModify":1636582943513,"name":"admaris","pinyin":"admaris","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/f1ce3d6f8a55a5fe565e8e4779bf5174","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":3,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖(非转发)","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":600761941,"gmtCreate":1638198483826,"gmtModify":1638198483969,"author":{"id":"4098950502646600","authorId":"4098950502646600","name":"admaris","avatar":"https://static.tigerbbs.com/f1ce3d6f8a55a5fe565e8e4779bf5174","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098950502646600","idStr":"4098950502646600"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600761941","repostId":"1188274579","repostType":4,"repost":{"id":"1188274579","kind":"news","pubTimestamp":1638192806,"share":"https://www.laohu8.com/m/news/1188274579?lang=zh_CN&edition=full","pubTime":"2021-11-29 21:33","market":"us","language":"en","title":"Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant<blockquote>辉瑞计划提高新冠药物产量以对抗奥密克戎病毒变种,股价上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1188274579","media":"TheStreet","summary":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivri","content":"<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.</p><p><blockquote>辉瑞首席执行官Albert Bourla证实,该制药商计划提高其Paxlovid抗病毒治疗药物的产量,这是针对新奥密克戎病毒变种传播的第一步。</blockquote></p><p> Pfizer shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.</p><p><blockquote>辉瑞表示,正准备提高新冠抗病毒治疗的产量,以应对新发现的奥密克戎病毒变种的潜在影响,该公司股价周一扩大涨幅。</blockquote></p><p> Pfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.</p><p><blockquote>辉瑞首席执行官Albert Bourla周一告诉CNBC,该制药商已承诺生产8000万剂其正在开发的抗病毒药物Paxlovid,高于之前预测的5000万剂。</blockquote></p><p> The antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.</p><p><blockquote>抗病毒治疗可能继续是对这种变异的有效防御,这种变异首先在南非被发现,尽管科学家仍然担心它可能对疫苗结构和天然免疫都有耐药性。</blockquote></p><p> Bourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding the drugmaker has the capability to make as many as 4 billion doses next year.</p><p><blockquote>Bourla还表示,辉瑞已经创建了一个新模板,如果需要,可以加快对抗奥密克戎病毒的新疫苗的开发,并补充说该制药商明年有能力生产多达40亿剂疫苗。</blockquote></p><p> Scientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.</p><p><blockquote>科学家和卫生官员尚未确定奥密克戎病毒是否对疫苗产生耐药性,世界卫生组织警告说,可能需要“几周时间”才能评估其全部潜力。</blockquote></p><p> Pfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.</p><p><blockquote>辉瑞股价周一盘前交易中上涨1.85%,开盘价为每股55.0美元。该股在周五午盘交易中触及54.94美元的历史新高。</blockquote></p><p> Earlier this month, Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food & Drug Administration, to the United States Department of Health and Human Services.</p><p><blockquote>本月早些时候,辉瑞表示将向美国卫生与公众服务部出售约1000万剂Paxlovid治疗药物,该药物目前正在接受美国食品和药物管理局的紧急使用批准(EUA)审查。</blockquote></p><p> At $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck & Co. MRK last month to buy 1.7 million doses its 'molnupiravir' treatment of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.</p><p><blockquote>每片530美元,比上个月与默克公司(Merck&Co.)达成的700美元的价格便宜约25%。MRK购买了170万剂“molnupiravir”,用于治疗有发展为严重疾病或住院风险的成年人的轻度至中度Covid。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant<blockquote>辉瑞计划提高新冠药物产量以对抗奥密克戎病毒变种,股价上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant<blockquote>辉瑞计划提高新冠药物产量以对抗奥密克戎病毒变种,股价上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2021-11-29 21:33</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.</p><p><blockquote>辉瑞首席执行官Albert Bourla证实,该制药商计划提高其Paxlovid抗病毒治疗药物的产量,这是针对新奥密克戎病毒变种传播的第一步。</blockquote></p><p> Pfizer shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.</p><p><blockquote>辉瑞表示,正准备提高新冠抗病毒治疗的产量,以应对新发现的奥密克戎病毒变种的潜在影响,该公司股价周一扩大涨幅。</blockquote></p><p> Pfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.</p><p><blockquote>辉瑞首席执行官Albert Bourla周一告诉CNBC,该制药商已承诺生产8000万剂其正在开发的抗病毒药物Paxlovid,高于之前预测的5000万剂。</blockquote></p><p> The antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.</p><p><blockquote>抗病毒治疗可能继续是对这种变异的有效防御,这种变异首先在南非被发现,尽管科学家仍然担心它可能对疫苗结构和天然免疫都有耐药性。</blockquote></p><p> Bourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding the drugmaker has the capability to make as many as 4 billion doses next year.</p><p><blockquote>Bourla还表示,辉瑞已经创建了一个新模板,如果需要,可以加快对抗奥密克戎病毒的新疫苗的开发,并补充说该制药商明年有能力生产多达40亿剂疫苗。</blockquote></p><p> Scientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.</p><p><blockquote>科学家和卫生官员尚未确定奥密克戎病毒是否对疫苗产生耐药性,世界卫生组织警告说,可能需要“几周时间”才能评估其全部潜力。</blockquote></p><p> Pfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.</p><p><blockquote>辉瑞股价周一盘前交易中上涨1.85%,开盘价为每股55.0美元。该股在周五午盘交易中触及54.94美元的历史新高。</blockquote></p><p> Earlier this month, Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food & Drug Administration, to the United States Department of Health and Human Services.</p><p><blockquote>本月早些时候,辉瑞表示将向美国卫生与公众服务部出售约1000万剂Paxlovid治疗药物,该药物目前正在接受美国食品和药物管理局的紧急使用批准(EUA)审查。</blockquote></p><p> At $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck & Co. MRK last month to buy 1.7 million doses its 'molnupiravir' treatment of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.</p><p><blockquote>每片530美元,比上个月与默克公司(Merck&Co.)达成的700美元的价格便宜约25%。MRK购买了170万剂“molnupiravir”,用于治疗有发展为严重疾病或住院风险的成年人的轻度至中度Covid。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron\">TheStreet</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188274579","content_text":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.\nPfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.\nThe antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.\nBourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding the drugmaker has the capability to make as many as 4 billion doses next year.\nScientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.\nPfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.\nEarlier this month, Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food & Drug Administration, to the United States Department of Health and Human Services.\nAt $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck & Co. MRK last month to buy 1.7 million doses its 'molnupiravir' treatment of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2319,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871264573,"gmtCreate":1637074928904,"gmtModify":1637074929057,"author":{"id":"4098950502646600","authorId":"4098950502646600","name":"admaris","avatar":"https://static.tigerbbs.com/f1ce3d6f8a55a5fe565e8e4779bf5174","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098950502646600","idStr":"4098950502646600"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/871264573","repostId":"1108846823","repostType":4,"repost":{"id":"1108846823","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637073553,"share":"https://www.laohu8.com/m/news/1108846823?lang=zh_CN&edition=full","pubTime":"2021-11-16 22:39","market":"us","language":"en","title":"Rivian rose nearly 10% in morning trade and hit an all-time high at 164.19 dollars<blockquote>Rivian早盘上涨近10%,创下164.19美元的历史新高</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1108846823","media":"Tiger Newspress","summary":"Rivian rose nearly 10% in morning trade and hit an all-time high at 164.19 dollars.Rivian (RIVN.US) ","content":"<p> Rivian rose nearly 10% in morning trade and hit an all-time high at 164.19 dollars.<img src=\"https://static.tigerbbs.com/5c173108ca81cbd959678e41253ff9a6\" tg-width=\"771\" tg-height=\"568\" referrerpolicy=\"no-referrer\">Rivian (RIVN.US) is in the final stage of negotiations on opening an automobile manufacturing and battery factory in the east of Atlanta, Georgia, USA. The source stressed that the negotiations have not yet been finalized and the details may change.</p><p><blockquote>Rivian早盘上涨近10%,触及164.19美元的历史新高。Rivian(RIVN.US)在美国佐治亚州亚特兰大市东部开设汽车制造和电池工厂的谈判正处于最后阶段。该消息人士强调,谈判尚未最终确定,细节可能会发生变化。</blockquote></p><p> It is reported that last week, it was reported that Rivian was actively looking for the location of an independent battery factory in addition to two new automobile assembly plants.</p><p><blockquote>据悉,上周有消息称,除了两家新的汽车组装厂外,Rivian正在积极寻找一家独立电池工厂的选址。</blockquote></p><p> At present, Rivian has built a factory in Normal, Illinois, USA, which produces the company's all-electric R1T pickup truck.</p><p><blockquote>目前,Rivian已经在美国伊利诺州诺默尔市建立了一家工厂,生产该公司的全电动R1T皮卡。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rivian rose nearly 10% in morning trade and hit an all-time high at 164.19 dollars<blockquote>Rivian早盘上涨近10%,创下164.19美元的历史新高</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRivian rose nearly 10% in morning trade and hit an all-time high at 164.19 dollars<blockquote>Rivian早盘上涨近10%,创下164.19美元的历史新高</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-16 22:39</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p> Rivian rose nearly 10% in morning trade and hit an all-time high at 164.19 dollars.<img src=\"https://static.tigerbbs.com/5c173108ca81cbd959678e41253ff9a6\" tg-width=\"771\" tg-height=\"568\" referrerpolicy=\"no-referrer\">Rivian (RIVN.US) is in the final stage of negotiations on opening an automobile manufacturing and battery factory in the east of Atlanta, Georgia, USA. The source stressed that the negotiations have not yet been finalized and the details may change.</p><p><blockquote>Rivian早盘上涨近10%,触及164.19美元的历史新高。Rivian(RIVN.US)在美国佐治亚州亚特兰大市东部开设汽车制造和电池工厂的谈判正处于最后阶段。该消息人士强调,谈判尚未最终确定,细节可能会发生变化。</blockquote></p><p> It is reported that last week, it was reported that Rivian was actively looking for the location of an independent battery factory in addition to two new automobile assembly plants.</p><p><blockquote>据悉,上周有消息称,除了两家新的汽车组装厂外,Rivian正在积极寻找一家独立电池工厂的选址。</blockquote></p><p> At present, Rivian has built a factory in Normal, Illinois, USA, which produces the company's all-electric R1T pickup truck.</p><p><blockquote>目前,Rivian已经在美国伊利诺州诺默尔市建立了一家工厂,生产该公司的全电动R1T皮卡。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108846823","content_text":"Rivian rose nearly 10% in morning trade and hit an all-time high at 164.19 dollars.Rivian (RIVN.US) is in the final stage of negotiations on opening an automobile manufacturing and battery factory in the east of Atlanta, Georgia, USA. The source stressed that the negotiations have not yet been finalized and the details may change.\nIt is reported that last week, it was reported that Rivian was actively looking for the location of an independent battery factory in addition to two new automobile assembly plants.\nAt present, Rivian has built a factory in Normal, Illinois, USA, which produces the company's all-electric R1T pickup truck.","news_type":1,"symbols_score_info":{"RIVN":0.9}},"isVote":1,"tweetType":1,"viewCount":3303,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":871264573,"gmtCreate":1637074928904,"gmtModify":1637074929057,"author":{"id":"4098950502646600","authorId":"4098950502646600","name":"admaris","avatar":"https://static.tigerbbs.com/f1ce3d6f8a55a5fe565e8e4779bf5174","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098950502646600","idStr":"4098950502646600"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/871264573","repostId":"1108846823","repostType":4,"repost":{"id":"1108846823","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637073553,"share":"https://www.laohu8.com/m/news/1108846823?lang=zh_CN&edition=full","pubTime":"2021-11-16 22:39","market":"us","language":"en","title":"Rivian rose nearly 10% in morning trade and hit an all-time high at 164.19 dollars<blockquote>Rivian早盘上涨近10%,创下164.19美元的历史新高</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1108846823","media":"Tiger Newspress","summary":"Rivian rose nearly 10% in morning trade and hit an all-time high at 164.19 dollars.Rivian (RIVN.US) ","content":"<p> Rivian rose nearly 10% in morning trade and hit an all-time high at 164.19 dollars.<img src=\"https://static.tigerbbs.com/5c173108ca81cbd959678e41253ff9a6\" tg-width=\"771\" tg-height=\"568\" referrerpolicy=\"no-referrer\">Rivian (RIVN.US) is in the final stage of negotiations on opening an automobile manufacturing and battery factory in the east of Atlanta, Georgia, USA. The source stressed that the negotiations have not yet been finalized and the details may change.</p><p><blockquote>Rivian早盘上涨近10%,触及164.19美元的历史新高。Rivian(RIVN.US)在美国佐治亚州亚特兰大市东部开设汽车制造和电池工厂的谈判正处于最后阶段。该消息人士强调,谈判尚未最终确定,细节可能会发生变化。</blockquote></p><p> It is reported that last week, it was reported that Rivian was actively looking for the location of an independent battery factory in addition to two new automobile assembly plants.</p><p><blockquote>据悉,上周有消息称,除了两家新的汽车组装厂外,Rivian正在积极寻找一家独立电池工厂的选址。</blockquote></p><p> At present, Rivian has built a factory in Normal, Illinois, USA, which produces the company's all-electric R1T pickup truck.</p><p><blockquote>目前,Rivian已经在美国伊利诺州诺默尔市建立了一家工厂,生产该公司的全电动R1T皮卡。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rivian rose nearly 10% in morning trade and hit an all-time high at 164.19 dollars<blockquote>Rivian早盘上涨近10%,创下164.19美元的历史新高</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRivian rose nearly 10% in morning trade and hit an all-time high at 164.19 dollars<blockquote>Rivian早盘上涨近10%,创下164.19美元的历史新高</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-16 22:39</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p> Rivian rose nearly 10% in morning trade and hit an all-time high at 164.19 dollars.<img src=\"https://static.tigerbbs.com/5c173108ca81cbd959678e41253ff9a6\" tg-width=\"771\" tg-height=\"568\" referrerpolicy=\"no-referrer\">Rivian (RIVN.US) is in the final stage of negotiations on opening an automobile manufacturing and battery factory in the east of Atlanta, Georgia, USA. The source stressed that the negotiations have not yet been finalized and the details may change.</p><p><blockquote>Rivian早盘上涨近10%,触及164.19美元的历史新高。Rivian(RIVN.US)在美国佐治亚州亚特兰大市东部开设汽车制造和电池工厂的谈判正处于最后阶段。该消息人士强调,谈判尚未最终确定,细节可能会发生变化。</blockquote></p><p> It is reported that last week, it was reported that Rivian was actively looking for the location of an independent battery factory in addition to two new automobile assembly plants.</p><p><blockquote>据悉,上周有消息称,除了两家新的汽车组装厂外,Rivian正在积极寻找一家独立电池工厂的选址。</blockquote></p><p> At present, Rivian has built a factory in Normal, Illinois, USA, which produces the company's all-electric R1T pickup truck.</p><p><blockquote>目前,Rivian已经在美国伊利诺州诺默尔市建立了一家工厂,生产该公司的全电动R1T皮卡。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108846823","content_text":"Rivian rose nearly 10% in morning trade and hit an all-time high at 164.19 dollars.Rivian (RIVN.US) is in the final stage of negotiations on opening an automobile manufacturing and battery factory in the east of Atlanta, Georgia, USA. The source stressed that the negotiations have not yet been finalized and the details may change.\nIt is reported that last week, it was reported that Rivian was actively looking for the location of an independent battery factory in addition to two new automobile assembly plants.\nAt present, Rivian has built a factory in Normal, Illinois, USA, which produces the company's all-electric R1T pickup truck.","news_type":1,"symbols_score_info":{"RIVN":0.9}},"isVote":1,"tweetType":1,"viewCount":3303,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600761941,"gmtCreate":1638198483826,"gmtModify":1638198483969,"author":{"id":"4098950502646600","authorId":"4098950502646600","name":"admaris","avatar":"https://static.tigerbbs.com/f1ce3d6f8a55a5fe565e8e4779bf5174","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098950502646600","idStr":"4098950502646600"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600761941","repostId":"1188274579","repostType":4,"repost":{"id":"1188274579","kind":"news","pubTimestamp":1638192806,"share":"https://www.laohu8.com/m/news/1188274579?lang=zh_CN&edition=full","pubTime":"2021-11-29 21:33","market":"us","language":"en","title":"Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant<blockquote>辉瑞计划提高新冠药物产量以对抗奥密克戎病毒变种,股价上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1188274579","media":"TheStreet","summary":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivri","content":"<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.</p><p><blockquote>辉瑞首席执行官Albert Bourla证实,该制药商计划提高其Paxlovid抗病毒治疗药物的产量,这是针对新奥密克戎病毒变种传播的第一步。</blockquote></p><p> Pfizer shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.</p><p><blockquote>辉瑞表示,正准备提高新冠抗病毒治疗的产量,以应对新发现的奥密克戎病毒变种的潜在影响,该公司股价周一扩大涨幅。</blockquote></p><p> Pfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.</p><p><blockquote>辉瑞首席执行官Albert Bourla周一告诉CNBC,该制药商已承诺生产8000万剂其正在开发的抗病毒药物Paxlovid,高于之前预测的5000万剂。</blockquote></p><p> The antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.</p><p><blockquote>抗病毒治疗可能继续是对这种变异的有效防御,这种变异首先在南非被发现,尽管科学家仍然担心它可能对疫苗结构和天然免疫都有耐药性。</blockquote></p><p> Bourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding the drugmaker has the capability to make as many as 4 billion doses next year.</p><p><blockquote>Bourla还表示,辉瑞已经创建了一个新模板,如果需要,可以加快对抗奥密克戎病毒的新疫苗的开发,并补充说该制药商明年有能力生产多达40亿剂疫苗。</blockquote></p><p> Scientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.</p><p><blockquote>科学家和卫生官员尚未确定奥密克戎病毒是否对疫苗产生耐药性,世界卫生组织警告说,可能需要“几周时间”才能评估其全部潜力。</blockquote></p><p> Pfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.</p><p><blockquote>辉瑞股价周一盘前交易中上涨1.85%,开盘价为每股55.0美元。该股在周五午盘交易中触及54.94美元的历史新高。</blockquote></p><p> Earlier this month, Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food & Drug Administration, to the United States Department of Health and Human Services.</p><p><blockquote>本月早些时候,辉瑞表示将向美国卫生与公众服务部出售约1000万剂Paxlovid治疗药物,该药物目前正在接受美国食品和药物管理局的紧急使用批准(EUA)审查。</blockquote></p><p> At $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck & Co. MRK last month to buy 1.7 million doses its 'molnupiravir' treatment of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.</p><p><blockquote>每片530美元,比上个月与默克公司(Merck&Co.)达成的700美元的价格便宜约25%。MRK购买了170万剂“molnupiravir”,用于治疗有发展为严重疾病或住院风险的成年人的轻度至中度Covid。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant<blockquote>辉瑞计划提高新冠药物产量以对抗奥密克戎病毒变种,股价上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant<blockquote>辉瑞计划提高新冠药物产量以对抗奥密克戎病毒变种,股价上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2021-11-29 21:33</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.</p><p><blockquote>辉瑞首席执行官Albert Bourla证实,该制药商计划提高其Paxlovid抗病毒治疗药物的产量,这是针对新奥密克戎病毒变种传播的第一步。</blockquote></p><p> Pfizer shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.</p><p><blockquote>辉瑞表示,正准备提高新冠抗病毒治疗的产量,以应对新发现的奥密克戎病毒变种的潜在影响,该公司股价周一扩大涨幅。</blockquote></p><p> Pfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.</p><p><blockquote>辉瑞首席执行官Albert Bourla周一告诉CNBC,该制药商已承诺生产8000万剂其正在开发的抗病毒药物Paxlovid,高于之前预测的5000万剂。</blockquote></p><p> The antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.</p><p><blockquote>抗病毒治疗可能继续是对这种变异的有效防御,这种变异首先在南非被发现,尽管科学家仍然担心它可能对疫苗结构和天然免疫都有耐药性。</blockquote></p><p> Bourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding the drugmaker has the capability to make as many as 4 billion doses next year.</p><p><blockquote>Bourla还表示,辉瑞已经创建了一个新模板,如果需要,可以加快对抗奥密克戎病毒的新疫苗的开发,并补充说该制药商明年有能力生产多达40亿剂疫苗。</blockquote></p><p> Scientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.</p><p><blockquote>科学家和卫生官员尚未确定奥密克戎病毒是否对疫苗产生耐药性,世界卫生组织警告说,可能需要“几周时间”才能评估其全部潜力。</blockquote></p><p> Pfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.</p><p><blockquote>辉瑞股价周一盘前交易中上涨1.85%,开盘价为每股55.0美元。该股在周五午盘交易中触及54.94美元的历史新高。</blockquote></p><p> Earlier this month, Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food & Drug Administration, to the United States Department of Health and Human Services.</p><p><blockquote>本月早些时候,辉瑞表示将向美国卫生与公众服务部出售约1000万剂Paxlovid治疗药物,该药物目前正在接受美国食品和药物管理局的紧急使用批准(EUA)审查。</blockquote></p><p> At $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck & Co. MRK last month to buy 1.7 million doses its 'molnupiravir' treatment of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.</p><p><blockquote>每片530美元,比上个月与默克公司(Merck&Co.)达成的700美元的价格便宜约25%。MRK购买了170万剂“molnupiravir”,用于治疗有发展为严重疾病或住院风险的成年人的轻度至中度Covid。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron\">TheStreet</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188274579","content_text":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.\nPfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.\nThe antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.\nBourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding the drugmaker has the capability to make as many as 4 billion doses next year.\nScientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.\nPfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.\nEarlier this month, Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food & Drug Administration, to the United States Department of Health and Human Services.\nAt $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck & Co. MRK last month to buy 1.7 million doses its 'molnupiravir' treatment of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2319,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}